Home/Pipeline/TAH2231

TAH2231

Opioid overdose reversal (Naloxone)

Phase 1/2Active

Key Facts

Indication
Opioid overdose reversal (Naloxone)
Phase
Phase 1/2
Status
Active
Company

About TAHO Pharmaceuticals

TAHO Pharma delivers novel transdermal and oral‑film drug formats to address unmet patient needs across cardiovascular, neurology, and oncology markets.

View full company profile